1. A phase 2a dose-escalation study of the safety, tolerability, pharmacokinetics and haemodynamic effects of BMS-986231 in hospitalized patients with heart failure with reduced ejection fraction;Tita;Eur J Heart Fail.,2017
2. Intravenous infusion of the novel HNO donor BMS-986231 is associated with beneficial inotropic, lusitropic, and vasodilatory properties in 2 canine models of heart failure;Hartman;JACC: Basic Translat Sci,2018
3. A phase 1 randomized study of single intravenous infusions of the novel nitroxyl donor BMS-986231 in healthy volunteers;Cowart;J Clin Pharmacol,2019
4. Photostability Testing of New Drug Substances and Products,1996
5. Stability Testing of new Drug Substances and Products,2003